The effect of intravitreal bevacizumab (avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration

Ehud Rechtman, Ingeborg Stalmans, Joseph Glovinsky, Christophe Breusegem, Joseph Moisseiev, Joachim van Calster, Alon Harris

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Purpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse amplitude (OPA). Methods: This was a two center prospective study (Sheba Medical Center, Israel, and University Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. Pearson correlation was used to evaluate the influence of various measured parameters on DCT-OPA. Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). A good correlation was found throughout the study between the DCT-intraocular pressure (IOP) and Goldmann IOP and between DCT-IOP and DCT-OPA. No change in OPA of bevacizumabtreated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between visits 1 and 3). No correlations were found between DCT-OPA and age, heart rate, systemic blood pressure, axial length, keratometry readings, and central corneal thickness. Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the safety profile of bevacizumab in AMD treatment.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalClinical Ophthalmology
Issue number1
StatePublished - 2011
Externally publishedYes


  • Bevacizumab
  • Blood flow
  • Choroid
  • Macular degeneration
  • Ocular pulse amplitude


Dive into the research topics of 'The effect of intravitreal bevacizumab (avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this